Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

Unusual Whales

Jul 27, 2026 at 11:02 AM

The company has announced its intention to file an Investigational New Drug (IND) application in the fourth quarter of 2026 and commence a Phase 1 study by the conclusion of the same year.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Neumora Therapeutics

NMRA.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--

LongbridgeAI